Fig. 3From: Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veteransCSP2014: VA-BRAVE timeline. PRN: as needed; WK: week; RES/Med VISIT: Research/Medication Administration Visit; 30 Day POST: 30Â day post study safety monitoring period. *At each visit, research assessments are collected. For more information on the schedule of assessments, refer to Table 1Back to article page